Join the club for FREE to access the whole archive and other member benefits.

Matthew O’Connor

Co-Chief Executive Officer and Co-founder of Cyclarity Therapeutics (former Underdog Pharmaceuticals)

Dr. O’Connor was awarded his Master’s degree in neuroscience from Northwestern Medical in 1999 and his PhD in Biochemistry from Baylor College of Medicine in 2005. His postdoctoral research includes work at UC Berkeley on muscle stem cells and aging. He is the author of 10 published manuscripts and lead inventor on the cyclodextrin patents. He is the outgoing VP of Research at SENS Research Foundation.

Visit website: https://underdogpharma.com/team/

 droki

See also: Company Cyclarity Therapeutics - Company developing simple and direct interventions targeting toxic forms of cholesterol for age-related diseases

Details last updated 11-Mar-2020

Matthew O’Connor is also referenced in the following:

2021 Interview With Dr Matthew OConnor

Matthew O'Connor discusses the progress of developing a new biotechnology platform

2022 Interview with Dr Matthew O’Connor

Matthew O'Connor discusses the development of new drugs based on cyclodextrins

Cyclarity Therapeutics

Company developing simple and direct interventions targeting toxic forms of cholesterol for age-related diseases

Interview with Dr Matthew O’Connor

Dr. Matthew O'Connor provides updates on a drug targeting the removal of 7-keto cholesterol

LessDeath

Research company that helps people join the Longevity Biotechnology industry through education and more

Longevity Hackers

Feature length documentary about longevity and radical life extension with due to be released in 2023

Longevity Summit Dublin 2022

18-Sep-2022 to 20-Sep-2022

Event gathering Global Longevity and Rejuvenation community in Dublin with many longevity movement superstars as speakers

Longevity Summit Dublin 2024

13-Jun-2024 to 16-Jun-2024

Event gathering Global Longevity and Rejuvenation community in Dublin by LEV Foundation (Dublin, Ireland)

SENS Annual Report 2020

Quick summary of SENS’ latest research projects and other activities

Translating Clearance of 7-Ketocholesterol - Matthew (Oki) O’Connor at Longevity Summit Dublin 2024

Matthew O’Connor delivers a keynote on the translation of 7-Ketocholesterol clearance

Matthew O’Connor Blog Posts

Highlights of Ending Age-Related Diseases 2020
10-Sep-2020

Highlights of Ending Age-Related Diseases 2020

Key points from 20 presentations from world-leading researchers

Matthew O’Connor News

Reason reports back from Rejuvenation Startup Summit 2024

Reason reports back from Rejuvenation Startup Summit 2024

Fight Aging! - 13-May-2024

A great summary of 25 speakers who are in various stages of platform building, drug discovery and clinical trials

Lifespan.io speaks to Cyclarity’s CEO for an update on its novel atherosclerosis treatment

Lifespan.io speaks to Cyclarity’s CEO for an update on its novel atherosclerosis treatment

Lifespan.io (LEAF) - 19-Feb-2024

The company is developing a drug called UDP-003 to treat the disease

'Innovation Passport' awarded for Underdog's novel compound intended for treating heart diseases

'Innovation Passport' awarded for Underdog's novel compound intended for treating heart diseases

Longevity Technology - 09-Sep-2021

Safe and potential compound shows disease-modifying effect by removing toxic cholesterol from blood